Biogennix bone grafting product cleared for expanded spine indication — 3 insights

Osteobiologics company Biogennix received FDA clearance March 5 for an expanded indication of its Agilon moldable bone grafting product.

Advertisement

Three insights:

1. Agilon is now cleared for use in posterolateral spine procedures when mixed with autograft.

2. The product features a high purity, type 1 fibrillar bovine collagen, which offers a site for cell attachment, migration, proliferation and differentiation.

3. The Irvine, Calif.-based company is accelerating national distribution of Agilon, which is available in three different sizes.

More articles on devices:
Rothman Orthopaedics surgeon to lead orthopedic oncology program
New Southeastern Spine Institute moves closer to completion
Kevin Lobo’s 8+ years as Stryker CEO: Leading 20+ acquisitions, boosting robotics & more

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.